Paper filler, really. There was never any doubt (Hart Scott, or otherwise) that the deal would not get done. But it is closed, and so that is moderately good news. Not at all unexpected -- so it is definitively "priced in" to Merck's NYSE print, as of early August 2024.
. . .[Merck] today announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases.
“By actively depleting B-cells, CN201 offers applications spanning both B-cell malignancies and autoimmune diseases. We look forward to building upon the foundational work started by the Curon team,” said Dr. Dean Y. Li, president, Merck Research Laboratories.
CN201 is currently being investigated in Phase 1 and Phase 1b/2 clinical trials for the treatment of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively. Preliminary data suggest CN201 has activity in patients with relapsed or refractory B-cell hematologic malignancies and is well tolerated, potentially leading to significant and sustained reductions in B-cell populations. . . .
Now you know. And. . . onward to another glorious fall day in the steel and glass canyons, tomorrow! Smile.
नमस्ते
No comments:
Post a Comment